1. Home
  2. IOVA vs KBDC Comparison

IOVA vs KBDC Comparison

Compare IOVA & KBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

N/A

Current Price

$3.53

Market Cap

1.0B

Sector

Health Care

ML Signal

N/A

Logo Kayne Anderson BDC Inc.

KBDC

Kayne Anderson BDC Inc.

N/A

Current Price

$13.67

Market Cap

941.8M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
IOVA
KBDC
Founded
2007
2021
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
941.8M
IPO Year
2008
2018

Fundamental Metrics

Financial Performance
Metric
IOVA
KBDC
Price
$3.53
$13.67
Analyst Decision
Buy
Buy
Analyst Count
12
5
Target Price
$10.45
$15.80
AVG Volume (30 Days)
9.3M
342.2K
Earning Date
05-25-2026
01-01-0001
Dividend Yield
N/A
13.89%
EPS Growth
32.28
N/A
EPS
N/A
1.23
Revenue
N/A
N/A
Revenue This Year
$60.04
$193.84
Revenue Next Year
$58.54
$9.00
P/E Ratio
N/A
$11.12
Revenue Growth
N/A
N/A
52 Week Low
$1.64
$13.06
52 Week High
$5.64
$17.60

Technical Indicators

Market Signals
Indicator
IOVA
KBDC
Relative Strength Index (RSI) 77.86 42.32
Support Level $2.11 $13.52
Resistance Level $3.73 $15.25
Average True Range (ATR) 0.19 0.32
MACD 0.09 -0.01
Stochastic Oscillator 97.56 32.50

Price Performance

Historical Comparison
IOVA
KBDC

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

About KBDC Kayne Anderson BDC Inc.

Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company that invests primarily in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through debt investments in middle-market companies.

Share on Social Networks: